<DOC>
	<DOCNO>NCT00004982</DOCNO>
	<brief_summary>Patients beta-thalassemia ( Cooley 's Anemia ) continue suffer transfusion-induced iron overload due inadequacy current iron-chelation therapy . Compliance use FDA-approved drug remove excess iron patient ( Desferal ) continue major problem despite convince evidence markedly reduce morbidity prolongs life . The full potential iron-chelation therapy realize orally-effective drug available . This small trial test premise combination drug new approach iron chelation therapy may reduce side effect increase efficacy . If drug give orally , may better chance find suitable alternative Desferal . Several combination experimental iron chelate drug use trial .</brief_summary>
	<brief_title>Combination Iron Chelation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Iron overload Overt cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>chelation therapy</keyword>
	<keyword>combination chemotherapy</keyword>
	<keyword>iron poisoning</keyword>
	<keyword>thalassemia</keyword>
	<keyword>chelate agent</keyword>
	<keyword>deferoxamine</keyword>
	<keyword>drug screen /evaluation</keyword>
	<keyword>therapy evaluation</keyword>
</DOC>